1336 related articles for article (PubMed ID: 11393383)
1. A randomized and double-blind comparison of isradipine and spirapril as monotherapy and in combination on the decline in renal function in patients with chronic renal failure and hypertension.
Petersen LJ; Petersen JR; Talleruphuus U; Møller ML; Ladefoged SD; Mehlsen J; Jensen HA
Clin Nephrol; 2001 May; 55(5):375-83. PubMed ID: 11393383
[TBL] [Abstract][Full Text] [Related]
2. The effects of isradipine and spirapril as monotherapy and combined therapy on blood pressure, renal hemodynamics, natriuresis, and urinary kallikrein in hypertensive nephropathy.
Maccariello ER; Genelhu de Abreu Fagundes V; Francischetti EA
Am J Hypertens; 1997 May; 10(5 Pt 1):541-5. PubMed ID: 9160765
[TBL] [Abstract][Full Text] [Related]
3. The effects of amlodipine and enalapril on renal function in adults with hypertension and nondiabetic nephropathies: a 3-year, randomized, multicenter, double-blind, placebo-controlled study.
Esnault VL; Brown EA; Apetrei E; Bagon J; Calvo C; DeChatel R; Holdaas H; Krcmery S; Kobalava Z;
Clin Ther; 2008 Mar; 30(3):482-98. PubMed ID: 18405787
[TBL] [Abstract][Full Text] [Related]
4. Acute and chronic effects of spirapril, alone or in combination with isradipine on kidney function and blood pressure in patients with reduced kidney function and hypertension.
Shohat J; Wittenberg C; Erman A; Rosenfeld J; Boner G
Scand J Urol Nephrol; 1999 Feb; 33(1):57-62. PubMed ID: 10100366
[TBL] [Abstract][Full Text] [Related]
5. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Rahman M; Pressel S; Davis BR; Nwachuku C; Wright JT; Whelton PK; Barzilay J; Batuman V; Eckfeldt JH; Farber M; Henriquez M; Kopyt N; Louis GT; Saklayen M; Stanford C; Walworth C; Ward H; Wiegmann T
Arch Intern Med; 2005 Apr; 165(8):936-46. PubMed ID: 15851647
[TBL] [Abstract][Full Text] [Related]
6. Effect of pentoxifylline on GFR decline in CKD: a pilot, double-blind, randomized, placebo-controlled trial.
Perkins RM; Aboudara MC; Uy AL; Olson SW; Cushner HM; Yuan CM
Am J Kidney Dis; 2009 Apr; 53(4):606-16. PubMed ID: 19216016
[TBL] [Abstract][Full Text] [Related]
7. Proteinuria predicts end-stage renal failure in non-diabetic chronic nephropathies. The "Gruppo Italiano di Studi Epidemiologici in Nefrologia" (GISEN).
Ruggenenti P; Perna A; Mosconi L; Matalone M; Pisoni R; Gaspari F; Remuzzi G
Kidney Int Suppl; 1997 Dec; 63():S54-7. PubMed ID: 9407422
[TBL] [Abstract][Full Text] [Related]
8. [Kidney function in hypertensive patients with chronic renal failure treated with the dual eliminated ACE-inhibitor spirapril].
Haufe CC; Sierakowski B; Jansa U; Stein G
Med Klin (Munich); 1994 Aug; 89(8):416-20. PubMed ID: 7968874
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the efficacy and tolerability of a low-dose combination of isradipine and spirapril in the first-line treatment of mild to moderate essential hypertension.
Pittrow DB; Antlsperger A; Welzel D; Wambach G; Schardt W; Weidinger G
Cardiovasc Drugs Ther; 1997 Nov; 11(5):619-27. PubMed ID: 9493699
[TBL] [Abstract][Full Text] [Related]
10. Strict blood-pressure control and progression of renal failure in children.
; Wühl E; Trivelli A; Picca S; Litwin M; Peco-Antic A; Zurowska A; Testa S; Jankauskiene A; Emre S; Caldas-Afonso A; Anarat A; Niaudet P; Mir S; Bakkaloglu A; Enke B; Montini G; Wingen AM; Sallay P; Jeck N; Berg U; Caliskan S; Wygoda S; Hohbach-Hohenfellner K; Dusek J; Urasinski T; Arbeiter K; Neuhaus T; Gellermann J; Drozdz D; Fischbach M; Möller K; Wigger M; Peruzzi L; Mehls O; Schaefer F
N Engl J Med; 2009 Oct; 361(17):1639-50. PubMed ID: 19846849
[TBL] [Abstract][Full Text] [Related]
11. Spirapril in chronic renal failure.
Stein G; Sierakowski B; Jansa U; Haufe CC
Blood Press Suppl; 1994; 2():54-60. PubMed ID: 8061847
[TBL] [Abstract][Full Text] [Related]
12. Long-term renoprotection by perindopril or nifedipine in non-hypertensive patients with Type 2 diabetes and microalbuminuria.
Jerums G; Allen TJ; Campbell DJ; Cooper ME; Gilbert RE; Hammond JJ; O'Brien RC; Raffaele J; Tsalamandris C;
Diabet Med; 2004 Nov; 21(11):1192-9. PubMed ID: 15498085
[TBL] [Abstract][Full Text] [Related]
13. Are angiotensin converting enzyme inhibitors superior to beta blockers in retarding progressive renal function decline?
van Essen GG; Apperloo AJ; Rensma PL; Stegeman CA; Sluiter WJ; de Zeeuw D; de Jong PE
Kidney Int Suppl; 1997 Dec; 63():S58-62. PubMed ID: 9407423
[TBL] [Abstract][Full Text] [Related]
14. An 18-week, prospective, randomized, double-blind, multicenter study of amlodipine/ramipril combination versus amlodipine monotherapy in the treatment of hypertension: the assessment of combination therapy of amlodipine/ramipril (ATAR) study.
Miranda RD; Mion D; Rocha JC; Kohlmann O; Gomes MA; Saraiva JF; Amodeo C; Filho BL
Clin Ther; 2008 Sep; 30(9):1618-28. PubMed ID: 18840367
[TBL] [Abstract][Full Text] [Related]
15. Initial angiotensin-converting enzyme inhibitor/calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertension.
Jamerson KA; Nwose O; Jean-Louis L; Schofield L; Purkayastha D; Baron M
Am J Hypertens; 2004 Jun; 17(6):495-501. PubMed ID: 15177521
[TBL] [Abstract][Full Text] [Related]
16. Effect of lacidipine, a dihydropyridine calcium antagonist on renal function of hypertensive patients with renal insufficiency.
Bailey RR; Shand BI; Smith AH; Robson RA; Lynn KL
Clin Nephrol; 1997 Oct; 48(4):224-9. PubMed ID: 9352156
[TBL] [Abstract][Full Text] [Related]
17. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group.
Klahr S; Levey AS; Beck GJ; Caggiula AW; Hunsicker L; Kusek JW; Striker G
N Engl J Med; 1994 Mar; 330(13):877-84. PubMed ID: 8114857
[TBL] [Abstract][Full Text] [Related]
18. In half of hypertensive diabetics, co-administration of a calcium channel blocker and an angiotensin-converting enzyme inhibitor achieved a target blood pressure of <130/80 mmHg: the azelnidipine and temocapril in hypertensive patients with type 2 diabetes (ATTEST) study.
Katayama S; Kawamori R; Iwamoto Y; Saito I; Kuramoto K;
Hypertens Res; 2008 Aug; 31(8):1499-508. PubMed ID: 18971523
[TBL] [Abstract][Full Text] [Related]
19. Effect of light exercise on renal hemodynamics in patients with hypertension and chronic renal disease.
Svarstad E; Myking O; Ofstad J; Iversen BM
Scand J Urol Nephrol; 2002; 36(6):464-72. PubMed ID: 12623513
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the effects of an angiotensin converting enzyme inhibitor and a calcium antagonist in hypertensive, macroproteinuric diabetic patients: a randomised double-blind study.
O'Donnell MJ; Rowe BR; Lawson N; Horton A; Gyde OH; Barnett AH
J Hum Hypertens; 1993 Aug; 7(4):333-9. PubMed ID: 8410924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
